We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
Ask ADVFN Intelligence (AI)
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic...
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose...
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.67 | -26.9789983845 | 6.19 | 6.81 | 4.51 | 195678 | 5.82694431 | CS |
| 4 | -1.57 | -25.7799671593 | 6.09 | 6.81 | 4.51 | 207542 | 6.05978648 | CS |
| 12 | -1.49 | -24.7920133111 | 6.01 | 7.77 | 4.51 | 160956 | 6.11739682 | CS |
| 26 | 1.07 | 31.0144927536 | 3.45 | 7.77 | 3.45 | 217368 | 5.46318439 | CS |
| 52 | 1.93 | 74.5173745174 | 2.59 | 7.77 | 2.245 | 230797 | 4.43070476 | CS |
| 156 | -13.29 | -74.6209994385 | 17.81 | 26.3 | 1.94 | 346730 | 6.90466948 | CS |
| 260 | -23.48 | -83.8571428571 | 28 | 50 | 1.94 | 305573 | 8.40510226 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
